Zhu Xiaoying, Lin Shuzhi, Liu Wei, Liu Qian, Yin Lin, Feng Bianling
Department of Pharmacy Administration, School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Front Public Health. 2025 Feb 24;13:1500603. doi: 10.3389/fpubh.2025.1500603. eCollection 2025.
The high-quality development of the traditional Chinese medicine (TCM) industry is dependent on supportive policies and requires higher levels of coordination and integration. National and local government policies must coordinate the integrated development of the TCM industry under modern governance principles. However, the policy structure and its impact on the development of the TCM industry have not been thoroughly explored from the perspectives of policy design and empirical evidence.
A TCMIDPs evaluation system was established using the PMC-Index model to quantitatively analyze TCMIDPs in China and Shaanxi Province. Additionally, principal component analysis (PCA) was used to comprehensively evaluate 51 enterprises in Shaanxi Province.
The policy analysis shows that the average PMC index of the 31 TCM industry development policies is 5.080, indicating that the areas and functions covered by these policies need improvement. The comprehensive evaluation reveals that pharmaceutical enterprises in Shaanxi Province still exhibit unbalanced development.
Future TCM industry policies should focus on long-term industrial development, incorporating comprehensive perspectives. Emphasis should be placed on strengthening enterprise R&D, accelerating pharmaceutical innovation, and promoting the holistic development of pharmaceutical enterprises.
中医药产业的高质量发展依赖于支持性政策，需要更高水平的协调与整合。国家和地方政府政策必须依据现代治理原则协调中医药产业的一体化发展。然而，尚未从政策设计和实证证据的角度对政策结构及其对中医药产业发展的影响进行深入探究。
运用PMC-Index模型建立中医药产业政策（TCMIDPs）评价体系，对中国及陕西省的中医药产业政策进行量化分析。此外，采用主成分分析（PCA）对陕西省51家企业进行综合评价。
政策分析表明，31项中医药产业发展政策的平均PMC指数为5.080，这表明这些政策所涵盖的领域和功能有待改进。综合评价显示，陕西省的制药企业发展仍不均衡。
未来中医药产业政策应着眼于产业长期发展，纳入全面视角。应着重加强企业研发，加速医药创新，推动制药企业整体发展。
